(688197.SH): The fourth generation ALK inhibitor SY-12321 has received approval for clinical trials.

Zhtng cijng APP xn, shuyo kngg (688197.SH) fb gnggo, gngs y jnr shudo guji yopn jind gunl j h'n qnf de "yow lnchng shyn pzhn tngzhsh", zuwi d s di ALK yzh j hu xun zhng yow, SY-12321 jionng dnyo zi jin binhu ln b xng shsh tush jng (ALK) yng xng wnqng sht yopn de lnchng shyn shnqng hud pzhn. Next News from Zhitong Finance APP: Shouyao Group (688197.SH) announced that the company recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. As a fourth-generation ALK inhibitor candidate drug, SY-12321 capsules as a monotherapy for ALK-positive advanced solid tumors have been approved for clinical trial application.